CIK 0001815442 · Large accelerated filer
Kymera Therapeutics, Inc.
Sign in to watch- Ticker
- KYMR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 812992166
- Phone
- 857-285-5314
- Business address
- 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472
- Former names
- Kymera Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,158,214
- in 2 filings, $3.4M under 10b5-1 plans
Net −$4,158,214. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-07-01 | Mainolfi Nello Chief Executive Officer | Sale 10b5-1 | −6,626 | $113.98 | $755K | 738,059 |
| 2026-07-01 | Mainolfi Nello Chief Executive Officer | Sale 10b5-1 | −24,105 | $114.96 | $2.8M | 713,954 |
| 2026-07-01 | Mainolfi Nello Chief Executive Officer | Sale 10b5-1 | −44,050 | $115.69 | $5.1M | 669,904 |
| 2026-07-01 | Mainolfi Nello Chief Executive Officer | Sale 10b5-1 | −3,336 | $116.56 | $389K | 666,568 |
| 2026-07-01 | Mainolfi Nello Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −80,000 | 135,559 | ||
| 2026-06-30 | Jacobs Bruce N. Chief Financial Officer | Option exercise 10b5-1 | +61,378 | $5.33 | $327K | 321,992 |
| 2026-06-30 | Jacobs Bruce N. Chief Financial Officer | Sale 10b5-1 | −1,500 | $110.54 | $166K | 320,492 |
| 2026-06-30 | Jacobs Bruce N. Chief Financial Officer | Sale 10b5-1 | −1,700 | $111.57 | $190K | 318,792 |
| 2026-06-30 | Jacobs Bruce N. Chief Financial Officer | Sale 10b5-1 | −1,100 | $112.79 | $124K | 317,692 |
| 2026-06-30 | Jacobs Bruce N. Chief Financial Officer | Sale 10b5-1 | −4,110 | $114.19 | $469K | 313,582 |
| 2026-06-30 | Jacobs Bruce N. Chief Financial Officer | Sale 10b5-1 | −51,375 | $114.77 | $5.9M | 262,207 |
| 2026-06-30 | Jacobs Bruce N. Chief Financial Officer | Sale 10b5-1 | −7,971 | $115.82 | $923K | 254,236 |
| 2026-06-30 | Jacobs Bruce N. Chief Financial Officer | Sale 10b5-1 | −6,153 | $116.99 | $720K | 248,083 |
| 2026-06-30 | Jacobs Bruce N. Chief Financial Officer | Sale 10b5-1 | −3,200 | $117.70 | $377K | 244,883 |
| 2026-06-30 | Jacobs Bruce N. Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −61,378 | 0 | ||
| 2026-06-29 | Booth Bruce Director | Sale 10b5-1 | −5,549 | $105.78 | $587K | 2,446,375 |
| 2026-06-29 | Booth Bruce Director | Sale 10b5-1 | −14,798 | $106.63 | $1.6M | 2,431,577 |
| 2026-06-29 | Booth Bruce Director | Sale 10b5-1 | −19,419 | $107.76 | $2.1M | 2,412,158 |
| 2026-06-29 | Booth Bruce Director | Sale 10b5-1 | −10,848 | $108.28 | $1.2M | 2,401,310 |
| 2026-06-29 | Booth Bruce Director | Sale 10b5-1 | −7,968 | $109.75 | $874K | 2,393,342 |
Page 2 of 25 · 493 trades